路透社4月1日 - 辉瑞公司周二表示，欧盟委员会批准了辉瑞公司的PFE.N呼吸道合胞病毒(RSV) 疫苗，用于预防由RSV引起的下呼吸道疾病，适用于18至59岁、患病风险较高的成年人。
辉瑞公司的Abrysvo疫苗获得了欧盟的扩大批准，该疫苗在3月份获得了欧洲药品管理局专家小组的支持。
这对竞争对手制药商葛兰素史克（GSK.L）来说是一个打击，该公司的RSV疫苗尚未在这一人群中获得批准。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.